Skip to main content
OpenTrials
Completed

NCT Number: NCT05073367

A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China

The main aim of the study is to review treatment therapies in people with Helicobacter pylori (H. pylori) infections in standard hospital settings in China.

In this study, the study doctors will review medical records of participants who have had H. pylori infections any time from 1st January 2019 to 31st December 2021. This study is about collecting existing data only; participants are not treated and do not need to visit a study doctor during this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

Loading trial locations.

About this study

This is a non-interventional, retrospective cohort study of participants who have evidence of H. pylori infection using pre-existing electronic medical record data in China. This study will evaluate the distribution of methods of eradication therapy among participants who received medications that were used in the eradication therapy for H. pylori infection.

Retrospective de-identified participant-level data will be collected primarily from hospitals in China between 1st January 2019 to 31st December 2021. The extracted electronic medical record dataset will include patient demographic information, visit information, diagnosis information, treatment information, and cost information (if available). All the participants will be assigned to a single observational cohort:

  • Participants with H. pylori

This multi-center study will be conducted in China. The overall study duration will be approximately 54 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants with a record of H. pylori infection diagnosis or positive result of H. pylori diagnostic testing between 1st January 2019 and 31st December 2021.

Exclusion criteria

Not applicable.

Treatment and study plan

Primary outcomes

  1. Percentage of Each Eradication Regimen Initially Prescribed After Index Date

    Time frame: Up to 36 months

    Eradication therapy in this study includes standard bismuth quadruple therapy, standard triple therapy, and dual therapy. Eradication therapy will be identified according to the combination of drugs that are prescribed on the same day. Index date will be defined as first diagnosis date or the first date of a positive result of H. pylori diagnostic testing whichever came first during the participant identification period. For the percentage calculation of each eradication regimen, the denominator is the total usage count of all standard eradication therapies taken by eligible participants and the numerator is the total usage count of each eradication therapy.

Secondary outcomes

  1. Percentage of Each Eradication Therapy's Treatment Duration From the Date of Prescription Until the Termination

    Time frame: From date of prescription up to 14 days

    Duration of eradication therapy is defined as the days in a medication-taking interval, which is equal to dosage by unit. Eradication therapy in this study includes standard bismuth quadruple therapy, standard triple therapy, and dual therapy. The duration of eradication therapy will be categorized into categorical variables including 7 days, 10 days, 14 days, or others. For percentage calculation of treatment duration of each eradication therapy, the denominator is the total usage count of all eradication therapies taken by eligible participants and the numerator is the count of the categorized duration of each eradication therapy.

  2. Percentage of Each Diagnostic Testing Used Before the Prescription of Eradication Therapy

    Time frame: Up to 36 months

    H. pylori diagnostic testing includes non-invasive testing (urea breath testing [UBT], fecal antigen testing, serological testing) and invasive testing (polymerase chain reaction [PCR], culture, rapid urease test [RUT] and histology). For percentage calculation of each diagnosis before eradication therapy, the denominator is the total count of diagnostic testing and the numerator is the count of each type of diagnostic testing.

  3. Percentage of Each Efficacy Evaluation Testing After the Termination of Eradication Therapy

    Time frame: Up to 36 months

    Efficacy evaluation testing is defined as H. pylori testing performed during the 28 days of efficacy evaluation period after treatment completion and this testing may extend to the follow-up period until observation period ends. For percentage calculation of efficacy evaluation testing after eradication therapy, the denominator is the total count of efficacy evaluation testing and the numerator is the count of each type of efficacy evaluation testing.

  4. Percentage of the Duration From the Termination of Eradication Therapy Until the Efficacy Evaluation Testing

    Time frame: Up to 36 months

    The duration is defined as the time period between the last day of taking medication of eradication therapy and the day receiving efficacy evaluation testing. The duration of eradication therapy will be categorized into categorical variables including less than or equal to (<=) 4 weeks or greater than (>) 4 weeks. For percentage calculation of efficacy evaluation testing after each eradication therapy, the denominator is the total count of efficacy evaluation testing and the numerator is the count of duration (<=4 weeks or >4 weeks) .

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

A Retrospective Observational Real-world Study to Evaluate Diagnosis Pattern, Treatment Pattern and Effectiveness of Eradication Treatment in Helicobacter Pylori (H. Pylori) Patients in China

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 11, 2021
Registry last updated
Apr 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.